Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
PMID: 20380480
2010
AIDS research and human retroviruses
Abstract: In the three ATV/r VFs, no baseline drug-associated mutations were detected by PG; for one patient CA detected RT: K65R; PR: I84V.
Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.
Abstract: Several patterns were frequently observed, including mutations in the NC-p1 cleavage site in combination with I50L, V82A, and I84V within the protease and mutations within the p1-p6 cleavage site in combination with D30N, I50V, and I84V within the protease.
Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
PMID: 19136678
2009
The Journal of antimicrobial chemotherapy
Abstract: Indinavir-associated mutations M46I/L, I84V and V82A/F/T developed earlier in subtype B across the time of exposure to that drug when compared with subtype G counterparts.
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
Introduction: It is, however, seen with significantly higher frequency in resistant viruses carrying the I84V mutation in PR and also specifically seen in resistant viruses carrying the I50V PR mutation, in association with L449F.
Introduction: Mutation L449F is frequently seen in viruses with mutation I84V in PR.
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
PMID: 19147519
2009
The Journal of antimicrobial chemotherapy
Abstract: CONCLUSIONS: Among the eight mutations with a negative impact on the virological response, I47V, I54M, T74P and I84V were previously described as darunavir resistance-associated mutations.
Abstract: Cochran-Armitage procedure identified eight mutations with a negative impact on the virological response, namely K14R, K20I, E34Q, I47V, I54M, K55R, T74P and I84V; and two mutations (E35D and V82A) with a positive impact.
Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.
Result: The contribution of individual HIV-2 PR mutations that confer phenotypic resistance to PIs have not been delineated; however, the emergence of mutations (K7R, G17N, K45R, M46I, V47A, I54M, V62A, I64V, V71I, I82F/L, I84V, L90M, and L99F) in PR in HIV-2 from individuals receiving PI-based therapy have been observed in previous studies.
Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure.
PMID: 18992847
2009
Infection, genetics and evolution
Abstract: In treated patients, K20M, D30N, G73S, I84V, and L90M, were more prevalent in subtype B, and K20T and N88S were more prevalent in subtype F1.
Table: I84V
Discussion: Finally, the comparison of both subtype groups matched for treatment time exposure to the PI class or, when appropriated, to specific PI showed that mutations K20M, D30N (under NFV-containing regimens or under NFV as the unique PI), G73S, I84V, and L90M (under N
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
PMID: 18955518
2009
Antimicrobial agents and chemotherapy
Abstract: GRL-02031 was potent against a variety of HIV-1(NL4-3)-based molecular infectious clones containing a single primary mutation reported previously or a combination of such mutations, although it was slightly less active against HIV-1 variants containing consecutive amino acid substitutions: M46I and I47V or I84V and I85V.
Abstract: Upon selection of HIV-1(NL4-3) in the presence of GRL-02031, mutants carrying L10F, L33F, M46I, I47V, Q58E, V82I, I84V, and I85V in the protease-encoding region and G62R (withi
Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007.
Result: For PIs, L90M appeared most often (n=6), followed by I84V (n=3).
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
PMID: 19734799
2009
Journal of acquired immune deficiency syndromes (1999)
Result: The sample from PID 30062 - which contained four NRTI-resistance mutations - also had the following minority protease inhibitor (PI) resistance mutations: M46I (0.8%), I84V (0.9%), and L90M (0.9%) (data not shown).
HIV mutation literature information.
PMID: 
2010
AIDS research and human retroviruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT